Cargando…

The Impact of HIV-1 Genetic Diversity on CRISPR-Cas9 Antiviral Activity and Viral Escape

The clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 system is widely explored for sequence-specific attack on HIV-1 proviral DNA. We recently identified dual-guide RNA (dual-gRNA) combinations that can block HIV-1 replication permanently in infected cell cultures and prevent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Darcis, Gilles, Binda, Caroline S., Klaver, Bep, Herrera-Carrillo, Elena, Berkhout, Ben, Das, Atze T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466431/ https://www.ncbi.nlm.nih.gov/pubmed/30871200 http://dx.doi.org/10.3390/v11030255

Ejemplares similares

CRISPR-Cas9 Dual-gRNA Attack Causes Mutation, Excision and Inversion of the HIV-1 Proviral DNA
por: Binda, Caroline S., et al.
Publicado: (2020)

Elimination of infectious HIV DNA by CRISPR–Cas9
por: Das, Atze T, et al.
Publicado: (2019)

Transient CRISPR-Cas Treatment Can Prevent Reactivation of HIV-1 Replication in a Latently Infected T-Cell Line
por: Liu, Ye, et al.
Publicado: (2021)

CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape
por: Wang, Gang, et al.
Publicado: (2016)

Tackling HIV Persistence: Pharmacological versus CRISPR-Based Shock Strategies
por: Darcis, Gilles, et al.
Publicado: (2018)

HIV-1 Escape From RNAi Antivirals: Yet Another Houdini Action?
por: Berkhout, Ben, et al.
Publicado: (2012)

CRISPR/Cas9: a double-edged sword when used to combat HIV infection
por: Liang, Chen, et al.
Publicado: (2016)

Extinction of all infectious HIV in cell culture by the CRISPR-Cas12a system with only a single crRNA
por: Gao, Zongliang, et al.
Publicado: (2020)

A Single H1 Promoter Can Drive Both Guide RNA and Endonuclease Expression in the CRISPR-Cas9 System
por: Gao, Zongliang, et al.
Publicado: (2018)

A CRISPR-Cas Cure for HIV/AIDS
por: Hussein, Mouraya, et al.
Publicado: (2023)

A combinatorial CRISPR-Cas12a attack on HIV DNA
por: Fan, Minghui, et al.
Publicado: (2022)

Efficient CRISPR-Cas13d-Based Antiviral Strategy to Combat SARS-CoV-2
por: Hussein, Mouraya, et al.
Publicado: (2023)

A conditionally replicating SIV variant that can be used to study the mechanism of protection conferred by live attenuated SIV vaccines
por: Das, Atze T, et al.
Publicado: (2011)

Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs
por: Darcis, Gilles, et al.
Publicado: (2020)

HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome
por: Westerhout, Ellen M., et al.
Publicado: (2005)

The viral Tat protein has no essential function in HIV-1 replication other than to activate transcription
por: Das, Atze T, et al.
Publicado: (2009)

Optimization of the doxycycline-dependent simian immunodeficiency virus through in vitro evolution
por: Das, Atze T, et al.
Publicado: (2008)

A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape
por: Lebbink, Robert Jan, et al.
Publicado: (2017)

Multiplexed tat-Targeting CRISPR-Cas9 Protects T Cells from Acute HIV-1 Infection with Inhibition of Viral Escape
por: Ophinni, Youdiil, et al.
Publicado: (2020)

CRISPR/Cas9-mediated viral interference in plants
por: Ali, Zahir, et al.
Publicado: (2015)

CRISPR/Cas9 as an antiviral against Orthopoxviruses using an AAV vector
por: Siegrist, Cathryn M., et al.
Publicado: (2020)

What is CRISPR/Cas9?
por: Redman, Melody, et al.
Publicado: (2016)

Cas9 specifies functional viral targets during CRISPR-Cas adaptation
por: Heler, Robert, et al.
Publicado: (2015)

Immunity and Viral Infections: Modulating Antiviral Response via CRISPR–Cas Systems
por: Brezgin, Sergey, et al.
Publicado: (2021)

Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs
por: Schopman, Nick CT, et al.
Publicado: (2010)

Role of Occult and Post-acute Phase Replication in Protective Immunity Induced with a Novel Live Attenuated SIV Vaccine
por: Berry, Neil, et al.
Publicado: (2016)

CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge
por: Lee, Choongho
Publicado: (2019)

Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir
por: Roychoudhury, Pavitra, et al.
Publicado: (2018)

On the primer binding site mutation that appears and disappears during HIV and SIV replication
por: Berkhout, Ben, et al.
Publicado: (2015)

How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir
por: Das, Atze T., et al.
Publicado: (2018)

Improvement of the CRISPR-Cpf1 system with ribozyme-processed crRNA
por: Gao, Zongliang, et al.
Publicado: (2018)

The Impact of CRISPR-Cas System on Antiviral Therapy
por: Bayat, Hadi, et al.
Publicado: (2018)

The Application of CRISPR/Cas Systems for Antiviral Therapy
por: Baddeley, Helen J. E., et al.
Publicado: (2021)

Reshuffling yeast chromosomes with CRISPR/Cas9
por: Fleiss, Aubin, et al.
Publicado: (2019)

The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like
por: Darcis, Gilles, et al.
Publicado: (2019)

Advances in CRISPR/Cas9
por: Zhu, Youmin
Publicado: (2022)

Type III CRISPR-Cas systems can provide redundancy to counteract viral escape from type I systems
por: Silas, Sukrit, et al.
Publicado: (2017)

The Advance of CRISPR-Cas9-Based and NIR/CRISPR-Cas9-Based Imaging System
por: Qiao, Huanhuan, et al.
Publicado: (2021)

HIV co-opts a cellular antiviral mechanism, activation of stress kinase PKR by its RNA, to enable splicing of rev/tat mRNA
por: Namer, Lise Sarah, et al.
Publicado: (2023)

Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification
por: Deans, Richard M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t2c1ej9qbb9lnvcen9kad82pc0